Activating Mutations in PIK3CD Disrupt the Differentiation and Function of Human and Murine CD4 T Cells
Overview
Authors
Affiliations
Background: Gain-of-function (GOF) mutations in PIK3CD cause a primary immunodeficiency characterized by recurrent respiratory tract infections, susceptibility to herpesvirus infections, and impaired antibody responses. Previous work revealed defects in CD8 T and B cells that contribute to this clinical phenotype, but less is understood about the role of CD4 T cells in disease pathogenesis.
Objective: We sought to dissect the effects of increased phosphoinositide 3-kinase (PI3K) signaling on CD4 T-cell function.
Methods: We performed detailed ex vivo, in vivo, and in vitro phenotypic and functional analyses of patients' CD4 T cells and a novel murine disease model caused by overactive PI3K signaling.
Results: PI3K overactivation caused substantial increases in numbers of memory and follicular helper T (T) cells and dramatic changes in cytokine production in both patients and mice. Furthermore, PIK3CD GOF human T cells had dysregulated phenotype and function characterized by increased programmed cell death protein 1, CXCR3, and IFN-γ expression, the phenotype of a T cell subset with impaired B-helper function. This was confirmed in vivo in which Pik3cd GOF CD4 T cells also acquired an aberrant T phenotype and provided poor help to support germinal center reactions and humoral immune responses by antigen-specific wild-type B cells. The increase in numbers of both memory and T cells was largely CD4 T-cell extrinsic, whereas changes in cytokine production and T cell function were cell intrinsic.
Conclusion: Our studies reveal that CD4 T cells with overactive PI3K have aberrant activation and differentiation, thereby providing mechanistic insight into dysfunctional antibody responses in patients with PIK3CD GOF mutations.
Golec D, Gazzinelli-Guimaraes P, Chauss D, Nagashima H, Yu K, Hill T bioRxiv. 2025; .
PMID: 39803425 PMC: 11722529. DOI: 10.1101/2024.10.28.620691.
IJspeert H, Dalm V, van Zelm M, Edwards E Immunother Adv. 2024; 4(1):ltae009.
PMID: 39679264 PMC: 11638974. DOI: 10.1093/immadv/ltae009.
Whalen J, Chandra A, Kracker S, Ehl S, Seidel M, Gulas I Clin Exp Immunol. 2024; 219(1).
PMID: 39673396 PMC: 11754865. DOI: 10.1093/cei/uxae107.
Singh A, Al Qureshah F, Drow T, Hou B, Rawlings D J Immunol. 2024; 213(2):135-147.
PMID: 38829130 PMC: 11232928. DOI: 10.4049/jimmunol.2400032.
Li Q, Wang W, Wu Q, Zhou Q, Ying W, Hui X J Clin Immunol. 2024; 44(4):102.
PMID: 38634985 PMC: 11026262. DOI: 10.1007/s10875-024-01705-w.